"Texas Digestive Disease Consultants in Southlake, Texas now offers Telemedicine and Telehealth services to provide greater convenience to our patients. With Telemedicine our patients will be able to receive gastroenterology treatment remotely from the comfort of their own home. We know that this will allow the residents of Southlake, Texas to receive a higher quality of gastrointestinal care from the qualified physicians of TDDC. Our Telemedicine provider is easy and free to use. Please contact our office to make an appointment today."

During the past decade, Texas Digestive Disease Consultants conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 30 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 25 clinical trials were completed. i.e. 277.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Digestive Disease Consultants" #1 sponsor was "Celgene" with 8 trials, followed by "Takeda" with 5 trials sponsored, "Gilead Sciences" with 4 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored and "Janssen Research & Development, LLC" with 4 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Digestive Disease Consultants" #1 collaborator was "Galapagos NV" with 3 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator and "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Texas Digestive Disease Consultants" are "Ulcerative Colitis" (13 trials), "Crohn Disease" (9 trials), "Colitis, Ulcerative" (8 trials), "Crohn's Disease" (5 trials) and "Eosinophilic Esophagitis" (2 trials). Many other conditions were trialed in "Texas Digestive Disease Consultants" in a lesser frequency.

Most popular intervention types in "Texas Digestive Disease Consultants" are "Drug" (48 trials), "Biological" (4 trials) and "Other" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Filgotinib" (6 trials), "Etrolizumab" (4 trials), "Vedolizumab" (4 trials) and "Guselkumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Digestive Disease Consultants" are 50 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Digestive Disease Consultants". undefined are not yet recruiting, 11 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 24 completed trials in Texas Digestive Disease Consultants, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Digestive Disease Consultants, 0 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 0 trials that are defined as “Not Applicable".